Immunogenicity and Tolerability of a SARS-CoV-2 TNX-1800, a Live Recombinant Poxvirus Vaccine Candidate, in Syrian Hamsters and New Zealand White Rabbits

• Published in: Viruses Vol. 15; no. 10; p. 2131
• Main Authors: Awasthi, Mayanka, Macaluso, Anthony, Goebel, Scott J., Luea, Erin, Noyce, Ryan S., Nasar, Farooq, Daugherty, Bruce, Bavari, Sina, Lederman, Seth
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.10.2023; MDPI
• Subjects: Antibodies; Attenuated vaccines; Brief Report; COVID-19 vaccines; DNA virus infections; DNA viruses; Edema; Erythema; genes; Genetic aspects; Genomes; horsepox; Immune response; Immunogenicity; Immunoglobulin G; Inoculation; Laboratory animals; live vaccines; Pandemics; Pharmaceutical research; Prevention; Proteins; Rabbits; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Skin; Spike protein; Statistical analysis; Testing; TNX-1800; vaccination; vaccine; vaccine platform; Vaccines; Viral proteins; Viral vaccines; viruses; United States; New Zealand; United States > US

TNX-1800 is a preclinical stage synthetic-derived live attenuated chimeric horsepox virus vaccine engineered to express the SARS-CoV-2 spike (S) gene. The objectives of this study were to assess the safety, tolerability, and immunogenicity of TNX-1800 administration in Syrian golden hamsters and New...